Cochrane · systematic review · CD015322
Pharmacological interventions for acute attacks of vestibular migraine
Webster, KE, Dor, A, Galbraith, K, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
ENTAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
2
No studies
1
Included studies
NR
No studies 1 · 33.3%Ungraded 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Triptans compared to placebo for acute attacks of vestibular migraine
Population: adults with acute attacks of vestibular migraine
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in vertigo (global score) ‐ up to 2 hours Triptans vs placebo | RR 0.84 [0.66, 1.07] | 2 studies · 262 participants | Very low Downgraded: risk of bias |
Change in vertigo Triptans vs placebo | no estimate extracted | NR | No studies |
Serious adverse events Triptans vs placebo | no estimate extracted | 1 study · 114 participants | Very low Downgraded: risk of bias |